Allarity Therapeutics Feed

	Tid*
2021-11-30	-	Kvartalsrapport 2021-Q3
2021-11-22	-	Extra Bolagsstämma 2021
2021-08-31	-	Kvartalsrapport 2021-Q2
2021-05-28	-	Kvartalsrapport 2021-Q1
2021-04-20	-	X-dag ordinarie utdelning ALLR 0.00 SEK
2021-04-19	-	Årsstämma
2021-03-31	-	Bokslutskommuniké 2020
2020-11-30	-	Kvartalsrapport 2020-Q3
2020-10-07	-	Extra Bolagsstämma 2020
2020-08-28	-	Kvartalsrapport 2020-Q2
2020-05-29	-	Kvartalsrapport 2020-Q1
2020-04-23	-	X-dag ordinarie utdelning ALLR 0.00 SEK
2020-04-22	-	Årsstämma
2020-03-31	-	Bokslutskommuniké 2019
2019-11-29	-	Kvartalsrapport 2019-Q3
2019-10-15	-	Extra Bolagsstämma 2019
2019-08-30	-	Kvartalsrapport 2019-Q2
2019-05-31	-	Kvartalsrapport 2019-Q1
2019-04-26	-	X-dag ordinarie utdelning ALLR 0.00 SEK
2019-04-25	-	Årsstämma
2019-03-29	-	Bokslutskommuniké 2018
2018-11-30	-	Kvartalsrapport 2018-Q3
2018-08-31	-	Kvartalsrapport 2018-Q2
2018-04-25	-	X-dag ordinarie utdelning ALLR 0.00 SEK
2018-04-24	-	Årsstämma
2018-03-23	-	Bokslutskommuniké 2017
2017-04-25	-	Extra Bolagsstämma 2017
2016-04-27	-	Split ALLR 1:20
2016-03-24	-	Bokslutskommuniké 2015
2016-02-09	-	Extra Bolagsstämma 2016
2015-08-31	-	Kvartalsrapport 2015-Q2
2015-04-21	-	Årsstämma
2015-03-26	-	Bokslutskommuniké 2014
2014-09-02	-	Extra Bolagsstämma 2014
2014-08-12	-	Kvartalsrapport 2014-Q2

Land	Danmark
Lista	First North Stockholm
Sektor	Hälsovård
Industri	Medicinteknik

2021-12-13 23:00:00 Allarity Therapeutics Announces Delisting and Last Day of Trading in the Company’s Shares on Nasdaq First North 1,74 SEK | -20,91% | 3,20 MSEK

2021-12-11 15:35:00 Allarity Therapeutics Announces Shareholder Acceptance of Share Swap Offer and Initiates Delisting of the Company’s Shares from Nasdaq First North 2,20 SEK | -8,26%

2021-11-24 23:15:00 Allarity Therapeutics A/S Publishes Offer Document Offering to Acquire Company Shares in Exchange for Shares in Allarity Therapeutics, Inc. with the Intent to Complete Recapitalization 2,41 SEK | -3,75% | 36,9 MSEK

2021-11-24 21:50:00 Grant of New Warrants and Resolutions on Existing Warrants 2,41 SEK | -3,75% | 36,9 MSEK

2021-11-23 08:00:00 Allarity Therapeutics Publishes Interim Report for the Period January – September 2021 2,60 SEK | -7,14% | 24,8 MSEK

2021-11-23 00:00:59 Minutes of Extraordinary General Meeting held on 22 November 2021 2,80 SEK | -1,69% | 51,6 MSEK

2021-11-11 08:30:00 Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus 2,18 SEK | +18,89% | 57,1 MSEK

2021-11-05 22:11:31 NOTICE OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF ALLARITY THERAPEUTICS A/S TO BE HELD ON NOVEMBER 22, 2021 1,83 SEK | +23,57%

2021-11-05 21:48:35 U.S. SEC Issues Order Declaring Allarity Therapeutics Inc.’s Form S-4 Registration Statement Effective Ahead of Planned Transition to U.S. Nasdaq 1,83 SEK | +23,57%

2021-09-23 09:00:00 Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate 1,67 SEK | +3,48% | 15,8 MSEK

2021-09-16 10:00:00 Allarity Therapeutics Presents Dovitinib Survival Data from DRP® Screened RCC Patients at ESMO 2021 Virtual Congress 1,80 SEK | +13,25% | 34,3 MSEK

2021-09-15 23:55:53 Update: Allarity Therapeutics Receives Approximately SEK 23.3 Million (US $2.7 Million) from Subscription to Warrants of Series ALLR TO 2 and TO 3 1,80 SEK | +13,25% | 34,3 MSEK

2021-09-14 23:06:29 Allarity Therapeutics Receives Approximately SEK 16.5 Million (US $1.9 Million) from Subscription to Warrants of Series ALLR TO 3 1,59 SEK | -0,56% | 3,93 MSEK

2021-08-31 21:19:54 MINUTES OF EXTRAORDINARY GENERAL MEETING 2021 1,77 SEK | +0,85% | 15,9 MSEK

2021-08-26 08:32:48 Allarity Therapeutics Announces Extraordinary Exercise Period for Warrants of Series ALLR TO 3 Set to August 30 – September 13, 2021 1,92 SEK | -0,05% | 29,9 MSEK

2021-08-23 08:45:00 Allarity Therapeutics Files Form S-4 Registration Statement with U.S. Securities & Exchange Commission (SEC) for Listing on U.S. Nasdaq 1,91 SEK | -16,37% | 83,5 MSEK

2021-08-23 07:00:00 Allarity Therapeutics Publishes Interim Report for the Period January – June 2021 1,91 SEK | -16,37% | 83,5 MSEK

2021-08-19 21:45:00 New Publication Date for Allarity Therapeutics’ Q2 2021 Interim Report 2,28 SEK | +29,19% | 78,3 MSEK

2021-08-18 08:26:20 Allarity Therapeutics Elaborates on the Contents of the Meeting Agenda for the Extraordinary General Meeting Announced on August 16, 2021 1,90 SEK | -0,52% | 36,9 MSEK

2021-08-16 23:18:13 NOTICE OF EXTRAORDINARY GENERAL MEETING 1,91 SEK | -9,82% | 44,2 MSEK

2021-08-05 13:00:00 Allarity Therapeutics’ oral PARP inhibitor, Stenoparib, demonstrates additional pre-clinical antiviral activity against new variants of Coronavirus 1,76 SEK | +8,71% | 155 MSEK

2021-07-26 08:30:00 Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven 0,94 SEK | +0,91% | 9,41 MSEK

2021-07-14 17:00:00 Allarity Therapeutics Issues Share Units as Payment-In-Kind for Services Rendered During Rights Issue in Q2 2021 0,94 SEK | +6,18% | 5,45 MSEK

2021-07-05 20:00:00 Allarity Therapeutics Receives Acceptance & Review Notification from U.S. FDA for Pre-Market Approval Application for Dovitinib-DRP® 0,97 SEK | -0,82% | 11,2 MSEK

2021-06-24 16:05:48 Last day of trading with Allarity Therapeutics A/S BTU 0,94 SEK | +6,92% | 2,14 MSEK

2021-06-14 13:00:00 Allarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib 0,89 SEK | -2,75% | 3,61 MSEK

2021-06-11 00:01:05 Allarity Therapeutics Completes Oversubscribed Rights Issue 0,93 SEK | +4,19% | 2,64 MSEK

2021-06-09 11:08:02 Allarity Therapeutics Publishes E-Poster Detailing the Molecular Pathways Covered by the Dovitinib-DRP® Companion Diagnostic 0,90 SEK | -1,54% | 1,60 MSEK

2021-05-28 13:45:00 Allarity Therapeutics Publishes Interim Report for the Period January – March 2021 0,94 SEK | -5,05% | 2,73 MSEK

2021-05-27 15:21:37 Allarity Therapeutics Publishes Prospectus Supplement 0,99 SEK | +7,61% | 3,56 MSEK

2021-05-21 07:21:31 Allarity Therapeutics Secures Investment from 3i Fund for Recapitalization, Transition to Listing on U.S. Nasdaq, and Advancing Pipeline of Priority Oncology Therapeutics 1,23 SEK | +48,16% | 51,9 MSEK

2021-05-21 07:00:00 Allarity Therapeutics Secures Investment from 3i Fund for Recapitalization, Transition to Listing on U.S. Nasdaq, and Advancing Pipeline of Priority Oncology Therapeutics 1,23 SEK | +48,16% | 51,9 MSEK

2021-05-19 08:30:00 Allarity Therapeutics to Conduct a Rights Issue of New Shares, and Publishes Prospectus regarding the Rights Issue 0,82 SEK | -4,53% | 1,76 MSEK

2021-05-05 23:11:50 Allarity Therapeutics Updates Preliminary Timetable for Planned Rights Issue 0,85 SEK | +0,12% | 0,75 MSEK

2021-04-29 16:31:01 Allarity Therapeutics To Present a Dovitinib-DRP® e-Poster at the European Association for Cancer Research (EACR) 2021 Virtual Congress 0,91 SEK | +3,68% | 0,80 MSEK

2021-04-15 21:00:54 MINUTES OF ANNUAL GENERAL MEETING 2021 0,88 SEK | -3,08% | 0,84 MSEK

2021-04-02 13:00:00 Allarity Therapeutics Submits Premarket Approval Application to U.S. FDA for DRP® Companion Diagnostic for Dovitinib 0,94 SEK | +8,97%

2021-03-31 23:00:00 Notice of Annual General Meeting 0,86 SEK | -3,33% | 0,53 MSEK

2021-03-31 08:30:00 Allarity Therapeutics Publishes its Annual Report for 2020 0,89 SEK | -2,70% | 1,05 MSEK

2021-03-23 08:30:00 Allarity Therapeutics plans fully guaranteed rights issue of approximately SEK 100 million 0,83 SEK | -7,22% | 3,80 MSEK

2021-03-09 13:00:00 Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma 0,99 SEK | +4,18% | 11,2 MSEK

2021-03-04 15:00:00 Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA® in Europe for the Treatment of Metastatic Breast Cancer 0,94 SEK | +5,34% | 12,3 MSEK

2021-02-24 16:19:57 Allarity Therapeutics Provides Update on Pre-Clinical Testing of Stenoparib’s Antiviral Activity Against New Variants of Coronavirus 1,14 SEK | +79,38% | 42,8 MSEK

2021-02-11 13:00:00 Allarity Therapeutics Draws Down the Fourth Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP 0,73 SEK | -5,81% | 2,76 MSEK

2021-01-26 13:00:00 Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential therapy for new highly infectious Strain B.1.1.7 of Coronavirus 0,75 SEK | -7,73% | 4,79 MSEK

2021-01-22 17:00:00 Allarity Therapeutics issues new shares to Aalto Capital in connection with services rendered 0,84 SEK | -0,35% | 0,75 MSEK

2020-12-22 13:00:00 Allarity Therapeutics Draws Down the Third Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP 0,86 SEK | -17,78% | 4,91 MSEK

2020-12-18 15:21:59 2020 in Review: A Letter from Allarity’s CEO 1,11 SEK | -2,96% | 1,59 MSEK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Allarity Therapeutics

Kalender

Beskrivning

Allarity Therapeutics

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden